What Centrus Energy Investors Missed Before A 62% Fall

If you had looked only at Centrus Energy’s Q3 2026 headline numbers, the story might seem straightforward. Revenue slipped compared with the prior year, yet net income jumped and the margin expanded sharply. Investors who held Centrus Energy from the start of the year are down 61.9%, including dividends. If that holding decision sat on a desk dated 1 January 2026, what in the record back then hinted that stronger profits might still pair with such a heavy loss?

This theme extends beyond Centrus Energy. See which of 17 nuclear energy infrastructure stocks may still merit a closer look.

The Two Centrus Energy Stories Investors Were Weighing

The shares cost US$243 at the start of the period, and Centrus Energy sat between two sharply different stories about its future.

The bullish view argued that a Fair Value of US$304, a price implied by its assumptions, made sense if exclusive HALEU enrichment capacity led to premium pricing and what analysts framed as supernormal margin expansion as Russian supply receded.

The bearish camp put Fair Value at US$106, again an implied price, and focused on dependence on a few government and utility contracts and the risk that changing nuclear policy could hit revenue and earnings predictability.

What The Results Changed For The Centrus Energy Debate

The clearest new fact was Centrus Energy’s Q3 2026 net income of US$31.6 million on US$55.5 million of revenue, which lifted net margin to 56.9%. That profitability outcome backed the optimistic story that talked about supernormal margin expansion, even though revenue slipped from US$74.9 million a year earlier, which kept a question mark over the growth part of that case. Overall, the evidence cut both ways.

The useful takeaway is simple. When a thesis hangs on margin power, as Centrus Energy’s did, you check net income and net margin first, then see whether top line trends are keeping up with the story you paid for.

Centrus Energy: What You Would Be Paying For Today

With Centrus Energy now trading at US$104 after a 61.9% share price fall from the start of the year, this Narrative’s Fair Value sits above the current price according to CentryResearch, an investor in the Simply Wall St Community.

The crux is HALEU. A buyer today would need to believe that domestic HALEU enrichment becomes a real bottleneck and that Centrus Energy converts its position into durable commercial-scale supply relationships.

"Among publicly traded companies, Centrus Energy is one of the most directly positioned to benefit from growing demand for HALEU. Centrus has decades of experience in uranium enrichment and is currently one of the few U.S.-based companies pursuing domestic HALEU production."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Before The Next Story Makes Headlines

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 45% below our estimate - uses branch automation and retail technology initiatives to emphasize software and services revenue.
• Company 2 - 47% below our estimate - expands from cystic fibrosis into kidney disease, gene editing, acute pain and endocrinology pipelines.
• Company 3 - 44% below our estimate - redirects capital from a sold label into core apparel platforms and shareholder-focused initiatives.

That is three of the list. See the full list of 32 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com